<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01631357</url>
  </required_header>
  <id_info>
    <org_study_id>CIH-RXB-201205001</org_study_id>
    <nct_id>NCT01631357</nct_id>
  </id_info>
  <brief_title>Study of Chemotherapy Combination With Autologous Cytokine-Induced Killer Cell Immunotherapy to Treat Lung Cancer</brief_title>
  <acronym>CIK</acronym>
  <official_title>Phase II/III Study of Chemotherapy Combination With Autologous Cytokine-Induced Killer Cell Immunotherapy in Stage IIIb-IV Squamous Non-Small-Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tianjin Medical University Cancer Institute and Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized, multicenter,open-label phase II/III study is to evaluate the effects of
      chemotherapy combination with autologous cytokine-induced killer Cell immunotherapy in
      patients with stage IIIb-IV squamous non-small-cell lung cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Phase II/III study,

        2. Randomized, multicenter, open-label study,

        3. Evaluated the effects of chemotherapy combination with autologous cytokine-induced
           killer Cell immunotherapy compared with chemotherapy in patients with stage IIIb-IV
           squamous non-small-cell lung cancer
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2014</start_date>
  <completion_date type="Actual">December 2018</completion_date>
  <primary_completion_date type="Actual">December 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>up to 3 years</time_frame>
    <description>PFS was measured from the date of randomization to the first disease progression or to death from any cause, whichever occurred first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>up to 3 years</time_frame>
    <description>OS was measured from the date of randomization until death from any cause.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <condition>Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Arm 1: CIK+CT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 1: We design chemotherapy combination with CIK cell immunotherapy as a experimential arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: CT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm 2: We design chemotherapy alone as a control arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CIK cell</intervention_name>
    <description>CIK cell injection</description>
    <arm_group_label>Arm 1: CIK+CT</arm_group_label>
    <other_name>Cytokine-induced killer cell</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine Injection</intervention_name>
    <description>Gemcitabine injection</description>
    <arm_group_label>Arm 1: CIK+CT</arm_group_label>
    <arm_group_label>Arm 2: CT</arm_group_label>
    <other_name>Gemcitabine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin injection</intervention_name>
    <description>Cisplatin injection</description>
    <arm_group_label>Arm 1: CIK+CT</arm_group_label>
    <arm_group_label>Arm 2: CT</arm_group_label>
    <other_name>Cisplatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Sex: male or female

          -  Age: from 18 to 80 years

          -  Histology: squamous non-small-cell lung cancer

          -  Clinical stage: from stage IIIb to stage IV

          -  Therapy: not received chemotherapy, radiotherapy, or immunotherapy before entry into
             this study

          -  Karnofsky performance status: more than 50%

          -  Expected survival: more than 2 months

          -  Laboratory tests results 7 days before the start of treatment:

        White blood cells: more than 3.0 × 109/L Platelets: more than 100 × 109/L Neutrophils: more
        than 1.5 × 109/L Hemoglobin: more than 80g/L Serum glutamate pyruvate transaminase: less
        than 2.5 folds of the upper normal limit (ULN) Serum glutamic-oxal (o) acetic transaminase:
        less than 2.5 × ULN Serum bilirubin: less than 1.25 × ULN Serum creatinine: less than 1.25
        × ULN

          -  pregnancy test: the test of women of child-bearing period must be negative 7 days
             before the start of treatment

          -  Contraception: male and female subjects of child-bearing period must adopt a reliable
             method of contraception before entry into this study until 30 days after stopping this
             study

          -  Informed consent: subject must have the ability to understand and voluntarily sign a
             written informed consent

        Exclusion Criteria:

          -  History of neoplasms: other neoplasms

          -  Medical history: mental disease, or congestive heart failure, or severe coronary
             artery disease, or cardiac arrhythmias, or concomitant corticosteroid therapy

          -  History of allergies: allergic to the study drugs

          -  Metastasis: clinical symptoms of brain metastasis

          -  Other clinical trial: the subject received other clinical trial before this study

          -  Laboratory tests: the serum test of human immunodeficiency virus, or hepatitis B
             virus, or hepatitis C virus was positive

          -  Woman: pregnant or lactating women

          -  Compliance: poor compliance

          -  History of neoplasms: other neoplasms
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiubao Ren, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Tianjin Medical University Cancer Institute and Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute and Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <study_first_submitted>May 27, 2012</study_first_submitted>
  <study_first_submitted_qc>June 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2012</study_first_posted>
  <last_update_submitted>October 31, 2019</last_update_submitted>
  <last_update_submitted_qc>October 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

